Explore advanced Thalassemia treatments at Liv Hospital, including curative Stem Cell Transplantation, Haploidentical protocols, and cutting-edge Gene Therapy options.
Send us all your questions or requests, and our expert team will assist you.
Treatment and Procedures for Thalassemia
For decades, the standard approach to treating Thalassemia was purely defensive. The goal was simply to keep the patient alive through a rigorous and often exhausting schedule of blood transfusions and iron removal. While these methods remain the foundation of stabilization, the philosophy at Liv Hospital has shifted to the offensive. We focus on curative interventions that aim to liberate the patient from the hospital setting permanently.
The treatment landscape has expanded dramatically. We now offer a spectrum of therapies ranging from optimized medical management to high-complexity cellular engineering. By utilizing Hematopoietic Stem Cell Transplantation (HSCT) and emerging Gene Therapy protocols, we can now offer a “biological reset” for the majority of patients, including those who were previously considered too old or without a suitable donor.
The answer to “How is thalassemia treated?” depends entirely on the severity of the condition and the patient’s long-term goals. At Liv Hospital, we categorize treatment into two distinct pathways: Supportive Management (maintaining health) and Curative Intervention (eliminating the disease).
For international patients, our treatment plans are customized based on genetic subtype and organ health. The modern therapeutic approach includes:
Before a patient can undergo a curative procedure, their body must be optimized. Many international patients arrive with a history of irregular transfusions or unmanaged iron levels, which makes immediate transplantation risky. Therefore, the first phase of treatment is often a period of “Hyper-Transfusion” and aggressive chelation.
The goal of this stabilization phase is threefold:
The gold standard for curing Thalassemia Major remains the Allogeneic Stem Cell Transplant. This procedure involves replacing the patient’s defective stem cells with healthy ones from a donor. It is a highly orchestrated process that unfolds in specific stages:
When successful, this procedure is transformative. The patient produces their own blood, the chronic anemia resolves, and the need for external blood transfusions ceases entirely.
Historically, the biggest barrier to a cure was finding a match. Only about 30 percent of patients have a fully matched brother or sister. For the remaining 70 percent, the search for a cure was often futile. However, Liv Hospital specializes in Haploidentical Stem Cell Transplantation, a revolutionary protocol that has changed these statistics.
A haploidentical transplant allows us to use a donor who is only a “half-match.” Since every child inherits half their genes from each parent, a mother or father is always a half-match for their child. In the past, these transplants carried high risks of rejection or Graft-vs-Host Disease (GVHD). Today, using advanced “post-transplant cyclophosphamide” protocols and specialized cell processing techniques, we can perform these transplants with success rates comparable to fully matched donor transplants. This means that virtually every patient has a donor waiting in their own family, removing the agonizing wait for a registry match.
Send us all your questions or requests, and our expert team will assist you.
For patients who do not have a suitable donor or who are at high risk for traditional transplant complications, Gene Therapy represents the absolute cutting edge of medicine. Unlike a transplant, which uses someone else’s cells, gene therapy uses the patient’s own stem cells.
The Gene Therapy process involves:
Benefits of Gene Therapy:
One of the persistent myths in Thalassemia care is that transplants are only for children. While it is true that younger patients generally have fewer complications, adults are no longer excluded from curative therapy. At Liv Hospital, we utilize Reduced Intensity Conditioning (RIC) regimens specifically designed for the adult body.
Standard “myeloablative” conditioning uses high-dose chemotherapy to completely destroy the marrow. RIC uses lower doses of chemotherapy and radiation. It relies more on the donor’s immune cells to finish the job of clearing out the old marrow (a graft-versus-marrow effect). This approach is much gentler on the organs, significantly reducing the toxicity to the liver and lungs. It opens the door for patients in their 30s, 40s, or even 50s to finally achieve transfusion independence after a lifetime of illness.
In some cases, surgical intervention is required before a transplant can be considered. The spleen acts as a filter for the blood. In Thalassemia, the spleen works overtime to destroy the abnormal red blood cells, causing it to grow to massive sizes (hypersplenism).
We perform Splenectomy (surgical removal) when:
At Liv Hospital, this is typically performed via laparoscopic (minimally invasive) surgery, ensuring a quick recovery so the patient can proceed to their definitive stem cell treatment without delay.
For young patients with a matched sibling donor, the cure rate is currently over 90 percent. For haploidentical transplants and adult patients, success rates have improved dramatically and now approach 80 to 85 percent in specialized centers.
The entire process usually requires a hospital stay of 4 to 6 weeks. This includes the conditioning chemotherapy, the infusion of cells, and the isolation period while waiting for the new immune system to grow (engraftment).
Yes. The chemotherapy used in the conditioning phase will cause temporary hair loss. However, the hair typically begins to grow back within 3 to 6 months after the treatment is completed.
The transplant stops the accumulation of new iron because you no longer need transfusions. However, it does not remove the iron already stored in your body. You will likely need to continue mild phlebotomy (blood removal) or chelation for a year or two post-transplant to fully clear the old iron.
Yes. Gene therapy has been approved in several countries for transfusion-dependent Beta Thalassemia. It has shown excellent results in allowing patients to become transfusion-free, though it is currently one of the most expensive medical treatments in the world.
Your Comparison List (you must select at least 2 packages)
